Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/04/02 22:55:39」(JST)

wiki en

Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second−generation cephalosporins. It is sold under the brand name Mefoxin.

Microbiology

Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and many strains of Enterobacter cloacae. Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin.^[1]

Cefoxitin is considered to be a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem).^[2]

Spectrum of Bacterial Susceptibility

Cefoxitin has a broad spectrum of activity and has been used in the treatment of skin, bone, respiratory and urinary tract infections. Susceptible bacteria include some Staphylococci, Enterococci, Streptococci, and others. The following represents MIC susceptibility data for a few medically significant microorganisms.

Escherichia coli: 0.2 μg/ml – 64 μg/ml
Haemophilus influenzae: 0.5 μg/ml – 12.5 μg/ml
Streptococcus pneumoniae: 0.2 μg/ml – 1 μg/ml

^[3]

References

^ Mefoxin Official FDA information at Drugs.com
^ Phillips I, Shannon K (1993). "Importance of beta-lactamase induction". Eur J Clin Microbiol Infect Dis. 12 Suppl 1: S19–26. PMID 8477758.
^ http://www.toku-e.com/Assets/MIC/Cefoxitin.pdf

This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. セフェム系 cephalosporins
2. 骨盤内炎症性疾患：治療 pelvic inflammatory disease treatment
3. 小児における急性虫垂炎：管理 acute appendicitis in children management
4. メチシリン耐性黄色ブドウ球菌の迅速な検出 rapid detection of methicillin resistant staphylococcus aureus
5. 成人における非結核性抗酸菌による骨髄炎の治療 treatment of osteomyelitis due to nontuberculous mycobacteria in adults

English Journal

Phenotypic detection of mecC-MRSA: cefoxitin is more reliable than oxacillin.

Skov R, Larsen AR, Kearns A, Holmes M, Teale C, Edwards G, Hill R.Author information Department of Microbiology and Infection Control, Statens Serum Institut, Artillerivej 5, Copenhagen 2300, Denmark.AbstractOBJECTIVES: To investigate the reliability of cefoxitin and oxacillin for the detection of mecC-positive Staphylococcus aureus.
The Journal of antimicrobial chemotherapy.J Antimicrob Chemother.2014 Jan;69(1):133-5. doi: 10.1093/jac/dkt341. Epub 2013 Sep 12.
OBJECTIVES: To investigate the reliability of cefoxitin and oxacillin for the detection of mecC-positive Staphylococcus aureus.METHODS: The susceptibility to cefoxitin and oxacillin of 62 mecC-positive S. aureus isolates was investigated using broth microdilution, agar dilution, Etest and disc diffu
PMID 24038776

Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.

Wybo I, Van den Bossche D, Soetens O, Vekens E, Vandoorslaer K, Claeys G, Glupczynski Y, Ieven M, Melin P, Nonhoff C, Rodriguez-Villalobos H, Verhaegen J, Piérard D.Author information Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium.AbstractOBJECTIVES: To collect recent data on the susceptibility of anaerobes to antimicrobial agents with known activity against anaerobes, and to compare them with results from previous Belgian multicentre studies.
The Journal of antimicrobial chemotherapy.J Antimicrob Chemother.2014 Jan;69(1):155-61. doi: 10.1093/jac/dkt344. Epub 2013 Sep 5.
OBJECTIVES: To collect recent data on the susceptibility of anaerobes to antimicrobial agents with known activity against anaerobes, and to compare them with results from previous Belgian multicentre studies.METHODS: Four hundred and three strict anaerobic clinical isolates were prospectively collec
PMID 24008826

Related Pictures

Cefoxitin Mefoxin - FDA prescribing information, side effects and uses Cefoxitin Intravenous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing Mefoxin - patient information, description, dosage and directions. cefoxitin intravenous Drug information on Uses, Side Effects, Interactions, and User Mefoxin in dextrose (iso-osmotic) intravenous : Uses, Side Effects, Interactions Cefoxitin - patient information, description, dosage and directions.

★リンクテーブル★

リンク元	「cefoxitin sodium」

「cefoxitin sodium」

Cefoxitin
Clinical data
Trade names	Mefoxin
AHFS/Drugs.com	Monograph
MedlinePlus	a682737
Pregnancy; category	B;
Routes of; administration	IV
ATC code	J01DC01 (WHO);
Pharmacokinetic data
Metabolism	minimal
Biological half-life	41-59 min
Excretion	85% urine
Identifiers
	IUPAC name (6S,7R)-3-(carbamoyloxymethyl)-7-methoxy-; 8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-; 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
CAS Number	35607-66-0 ;
PubChem CID	441199;
DrugBank	DB01331 ;
ChemSpider	389981 ;
UNII	6OEV9DX57Y;
KEGG	D02345 ;
ChEBI	CHEBI:209807 ;
ChEMBL	CHEMBL996 ;
ECHA InfoCard	100.047.841
Chemical and physical data
Formula	C16H17N3O7S2
Molar mass	427.454 g/mol
3D model (Jmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)Cc3sccc3)COC(=O)N)C(=O)O ;
	InChI InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1 ; Key:WZOZEZRFJCJXNZ-ZBFHGGJFSA-N ;
(what is this?) (verify)